Inflammation and prostate cancer: a future target for prevention and therapy? (Q37025056)

17 August 2017

1 reference

title

Inflammation and prostate cancer: a future target for prevention and therapy? (English)

1 reference

17 August 2017

0 references

1 reference

David Stock

1

1 reference

17 August 2017

Patti A Groome

series ordinal

2

1 reference

17 August 2017

D Robert Siemens

series ordinal

3

1 reference

17 August 2017

publication date

1 February 2008

1 reference

Urologic Clinics of North America

17 August 2017

published in

1 reference

17 August 2017

volume

35

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

117-30; vii

1 reference

Epidemiology of prostate cancer

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Changing trends of prostate cancer in Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The microenvironment of the tumour-host interface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The role of inflammation in the pathogenesis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Tumour-educated macrophages promote tumour progression and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Epidemiologic association between prostatitis and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Prostatitis and prostate cancer: implications for prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Prostatitis as a risk factor for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

7 January 2021

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Chemical basis of inflammation-induced carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

ras, p53 and HPV status in benign and malignant prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Prevention of human cancer by modulation of chronic inflammatory processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Putting tumours in context

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Dual roles of E-cadherin in prostate cancer invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Matrix metalloproteinase-induced genomic instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Oxidative and nitrative DNA damage as biomarker for carcinogenesis with special reference to inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Human prostate cancer precursors and pathobiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cancer-susceptibility genes. Gatekeepers and caretakers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Soluble mediators of inflammation during tumor development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Inflammatory chemokines in cancer growth and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Role of tumor-associated macrophages in tumor progression and invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Expression of CCL5 (RANTES) and CCR5 in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

TNF-alpha in promotion and progression of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

HIV-1 entry inhibitors: evading the issue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Activators and target genes of Rel/NF-kappaB transcription factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Differential metastasis-associated gene analysis of prostate carcinoma cells derived from primary tumor and spontaneous lymphatic metastasis in nude mice with orthotopic implantation of PC-3M cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Concomitant reduction of matrix metalloproteinase-2 secretion and intracellular reactive oxygen species following anti-sense inhibition of telomerase activity in PC-3 prostate carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Nonsteroidal anti-inflammatory drug reduces neutrophil and macrophage accumulation but does not improve tendon regeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase-2 and prostate carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Signalling networks regulating cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenases in cancer: progress and perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyanidin attenuates PGE2 production and cyclooxygenase-2 expression in LNCaP human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Lipopolysaccharide and TNF-alpha activate the nuclear factor kappa B pathway in the human placental JEG-3 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Silica induces human cyclooxygenase-2 gene expression through the NF-kappaB signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Expression of cyclooxygenase-2 in prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase-2 promotes prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

The role of cyclooxygenase-2 in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Regular use of aspirin and prostate cancer risk (United States)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Aspirin and the risk of prostate cancer

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.09.006

10.1016/J.UCL.2007.09.006

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference